Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody

• Status: Unknown status
• Trial end date: 2016-12-01

Summary

The purpose of the study is to investigate effect of immunotherapy in intractable cryptogenic epilepsy patients with autoimmune antibody.

• Phase: Phase 4

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Antibodies; Autoantibodies; Immunoglobulins; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate